Vanda Pharmaceuticals, Inc.
9620 Medical Center Drive
About Vanda Pharmaceuticals, Inc.Vanda is a specialty pharmaceutical company focused on the development and commercialization of novel therapies to address high unmet medical needs and improve the lives of patients.
Founders: Mihael Hristos Polymeropoulos, Argeris Karabelas
CEO: Mihael Hristos Polymeropoulos
CFO: James Kelly
Please click here for Vanda job opportunities.
Please click here for clinical trial information.
343 articles with Vanda Pharmaceuticals, Inc.
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2020 on Wednesday, October 28, 2020 , after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, October 28, 2020 , during w
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provided an update on its development program for tradipitant
Vanda Pharmaceuticals' Interim Analysis from ODYSSEY Study Shows Tradipitant may Accelerate Clinical Improvement in Patients with COVID-19 Pneumonia
Vanda Pharmaceuticals Inc. reported that interim analysis showed tradipitant may accelerate clinical improvement in SARS-CoV-2 pneumonia in the ODYSSEY study.
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the second quarter ended June 30, 2020.
FDA Accepts and Grants Priority Review of Vanda's Applications for HETLIOZ® (tasimelteon) in the Treatment of Smith-Magenis Syndrome
Vanda Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration has accepted for priority review Vanda's applications for Smith-Magenis Syndrome.
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2020 on Wednesday, August 5, 2020, after the market closes.
FDA grants authorization for Individual Patient Expanded Access Protocol for the use of tradipitant for gastroparesis
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) announced today that the U.S. Food and Drug Administration (FDA) has authorized a single patient in an Individual Patient Expanded Access protocol (VP-VLY-686-3303).
Vanda Pharmaceuticals Inc., announced that Vanda will hold its 2020 Annual Meeting of Stockholders in a virtual-only format due to public health concerns related to the COVID-19 pandemic and to protect the health and well-being of its stockholders, directors, employees and the public.
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today released a letter (below) from Mihael H. Polymeropoulos , M.D., President and CEO of Vanda Pharmaceuticals, proposing an approach to Clinical Trial Data Sharing in order to facilitate discovery and clinical utility of COVID-19 therapeutics. Vanda is also involved in the development of
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Federal District Court in Washington D.C. granted Vanda's motion to dismiss a False Claims Act lawsuit filed against the company.
Vanda Pharmaceuticals Announces Agreement with FDA on Resubmission of the Application for HETLIOZ® for the Treatment of Patients with Smith-Magenis Syndrome
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that following the completion of a Type A Meeting with the U.S. Food and Drug Administration (FDA) on May 8, 2020 , it has reached agreement with the FDA to resubmit its application for HETLIOZ® (tasimelteon) for the treatment of Smith-Magenis Syndrome (SMS). As previously
Vanda Pharmaceuticals Inc. announced it will release results for the first quarter 2020 on Wednesday, May 6, 2020, after the market closes.
4/20/2020There’s plenty of news related to clinical trials related to COVID-19, but it does seem to be drowning out non-COVID-19-related clinical trials. Here’s a look.
It will test the use of tradipitant for neurogenic inflammation of the lung secondary to SARS-CoV-2 infection.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 16, 2020.
Vanda Pharmaceuticals Announces Initiation of "CALYPSO" to Study the Role of Genetic Variation in COVID-19 Infections in Collaboration With University of Washington Medicine
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the initiation of the CALYPSO program to study the role that human genetic variations play in SARS-CoV-2 ("COVID-19") infection and disease progression.
Vanda Pharmaceuticals, Northwell Health Conduct ODYSSEY Trial In Patients With Severe COVID-19 Pneumonia
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and Northwell Health's research arm, The Feinstein Institutes for Medical Research , today announced enrollment of the first patient in Vanda's clinical trial, ODYSSEY VLY-686-3501 (NCT04326426), yesterday at Lenox Hill Hospital in New York City . ODYSSEY is a Phase III double
Vanda Pharmaceuticals Inc. And The University of Illinois at Chicago Announce Partnership To Identify Novel Antivirals Against COVID-19
Vanda Pharmaceuticals Inc. ("Vanda") (Nasdaq: VNDA) and the University of Illinois at Chicago (UIC) today announced a research partnership focused on the investigation of small molecules with the potential to treat COVID-19.
Vanda Pharmaceuticals Announces the Initiation of ODYSSEY, an FDA Approved Clinical Study of Tradipitant in Hospitalized Patients with Severe COVID-19 Pneumonia
Vanda Pharmaceuticals Inc. ("Vanda") (Nasdaq: VNDA) today announced the initiation of clinical study, ODYSSEY VLY-686-3501, in hospitalized patients with COVID-19.
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), today announced that it will participate at the following upcoming investor conferences in March 2020 : The Cowen and Company 40th Annual Health Care Conference in Boston on Tuesday, March 3, 2020 . A corporate presentation is scheduled for 8:40 a.m. Eastern Time